Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

A panelist discusses how healthcare providers must become lifestyle coaches who understand patients' daily routines and circumstances to develop realistic medication schedules that address practical barriers to adherence in complex polypharmacy regimens.

Managing Resistant Hypertension: Unpacking Adherence and Polypharmacy

Panelists discuss how standard ACE therapy leaves multiple pathways unblocked in resistant hypertension, with spironolactone being the most evidence-based fourth-line therapy despite limitations, while emerging therapies target sympathetic nervous system overactivity, aldosterone excess, and endothelin-mediated vasoconstriction.

Efficacy of Current Standard-of-Care Treatments for Resistant Hypertension

Panelists discuss how lifestyle modifications, particularly sodium restriction and plant-based diets, form the foundation of resistant hypertension management, with innovative approaches like teaching kitchens and food-as-medicine programs being more effective than traditional diet counseling.

Lifestyle vs Medical Treatment

A panelist discusses how treatment strategies progress from standard 3-drug regimens (thiazide diuretics, calcium channel blockers, and ACE inhibitors/ARBs) to fourth-line options like endothelin antagonists or aldosterone antagonists, while addressing information overload and the need for weight management drugs.

Treatment Strategies for Resistant Hypertension: A Multipronged Balancing Act

Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.

Cardiology Month in Review: June 2025

This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.


FDA News Recap: June 2025

The results of the ZENITH trial have encouraged the expansion of sotatercept’s label to patients with prior background therapy.

FDA Accepts Application for Sotatercept-csrk Label Expansion in PAH

Panelists discuss how patients with resistant hypertension should be referred to specialists after 3 to 6 months of unsuccessful treatment, emphasizing that while primary care providers can manage most hypertension cases, specialists with particular interest and experience are needed for complex cases.

Collaborating in a Multidisciplinary Team to Control Resistant Hypertension

Panelists discuss how resistant hypertension is defined as blood pressure remaining above 130/80 mm Hg despite 3 medications, including a diuretic, affecting 10% to 15% of hypertensive patients, and how to differentiate true resistance from pseudoresistance caused by adherence issues, improper measurement, white coat effect, and interfering medications.

Defining Resistant Hypertension

A panelist discusses how comorbidities like obesity, diabetes, and kidney disease significantly contribute to resistant hypertension through mechanisms including dietary sodium excess, arterial stiffening, and hormonal disruption from the renin-aldosterone system

How Poor Diet and Comorbidities Affect Resistant Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.